subscribeSubscribe
Jazz to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca Data

Jazz to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca Data
PR NEWSWIRE
15 Mar 2023
Share Share
PharmaMar Gets Approval of Zepzelca For Metastatic Small Cell Lung Cancer

PharmaMar Gets Approval of Zepzelca For Metastatic Small Cell Lung Cancer
KALKINEMEDIA
09 Mar 2023
Share Share
Jazz`s lung cancer drug keeps approval despite failed trial

Jazz`s lung cancer drug keeps approval despite failed trial
Angus Liu FIERCE PHARMA
27 Oct 2022
Share Share
Jazz Pharma Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial

Jazz Pharma Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial
PRNEWSWIRE
24 Mar 2022
Share Share
PharmaMar signs a new licensing and commercialization agreement with Eczacibasi

PharmaMar signs a new licensing and commercialization agreement with Eczacibasi
PRNEWSWIRE
23 Dec 2021
Share Share
PharmaMar, Jazz Announce Initiation of Confirmatory Phase 3 Trial of Zepzelca

PharmaMar, Jazz Announce Initiation of Confirmatory Phase 3 Trial of Zepzelca
PRNEWSWIRE
11 Dec 2021
Share Share
PharmaMar Partners with Lotus Pharmaceutical for lurbinectedin in Taiwan

PharmaMar Partners with Lotus Pharmaceutical for lurbinectedin in Taiwan
FIRSTWORDPHARMA
11 Nov 2021
Share Share
PharmaMar announces the approval of ZepzelcaTM

PharmaMar announces the approval of ZepzelcaTM
PRESS RELEASE
30 Sep 2021
Share Share
New Therapy to Treat Advanced SCLC,ZEPZELCA(lurbinectedin) Approved in Singapore

New Therapy to Treat Advanced SCLC,ZEPZELCA(lurbinectedin) Approved in Singapore
PRNEWSWIRE
22 Sep 2021
Share Share
New Therapy to Treat Advanced SCLC Approved for Australian Patients

New Therapy to Treat Advanced SCLC Approved for Australian Patients
PRNEWSWIRE
14 Sep 2021
Share Share